FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Clinical trials for FLT3-MUTATED ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new FLT3-MUTATED ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for FLT3-MUTATED ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with Tough-to-Treat leukemia
Disease control OngoingThis study is testing the safety and effectiveness of adding a drug called midostaurin to standard chemotherapy for children newly diagnosed with a specific genetic type of acute myeloid leukemia (AML). It involves 22 children and aims to see if this combination can better contro…
Matched conditions: FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New hope for frail AML patients: testing a gentler, targeted drug cocktail
Disease control OngoingThis study is testing a new combination of three oral and injectable drugs (gilteritinib, venetoclax, and azacitidine) for adults newly diagnosed with a fast-growing type of acute myeloid leukemia (AML) who are too old or have other health problems that make standard chemotherapy…
Matched conditions: FLT3-MUTATED ACUTE MYELOID LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Mar 20, 2026 14:47 UTC